

Drug Name/Manufacturer	Dose/Package size	Press Release Date	Reason Discontinued
promethazine	25 mg/1 mL, 1 vial Single-Dose (NDC 0703-2191-01), 50 mg/1 mL Injection, 1 Vial Single-Dose (NDC 0703-2201-01), 25 mg/1 mL, 25 in 1 tray (NDC 0703-2191-04), 50 mg/1 mL, 25 in 1 tray (NDC 0703-2201-04)	12/19/2019	Teva made a business decision to discontinue this product.
Gammunex -C (Grifols)	10% NDC13533-800-71 lot A4GKD00232 (6/8/2022)	12/16/2019; 12/31/2019	higher rate of allergic/hypersensitivity type reactions
Budesonide ER tablets	not given	12/6/2019	not given
Paclitaxel Injection (HQ Specialty Pharma)	30mg/5mL, 100mg/16.7mL, 300mg/50mL = (6mg/mL)	7/3/2019	Distributed by WG Critical Care. Discontinuance: no longer commercially viable
Clozapine (FazaClo®) Orally Disintegrating Tablets	12.5, 25, 100, 150 (8 blister, 200 mg tablets)	11/22/19	A commercial decision has been made to discontinue the sale of the product.
Clozapine (FazaClo®) Orally Disintegrating Tablets	25, 150, 200 mg tablets, 100 ct bottles	11/22/19	A commercial decision has been made to discontinue the sale of the product.
Phenobarbital Oral Soln	1 pint 473mL (NDC 16571-330-16)	11/25/2019	N/A
Loxapine Capsules (Lannett Company, Inc.)	5, 10, 25, 50mg 1000 count bottles	11/25/2019	N/A
Ketoprofen Capsules (Avet Pharmaceuticals)	25 mg, 100 and 1000 ct bottles (NDC 23155-020-01, 23155-020-10)	11/25/2019	Avet is no longer marketing the 25 mg strength, Marketed by Sterling Knight Pharmaceuticals, LLC. Contact information: 662-661-3232.
Hydrocortisone Acetate Suppository (Torrent)	Boxes of 12, 24, and 100 suppositories	11/25/2019	N/A
Nystatin (Par)	15, 30, 60g (100,000 USP units per gram)	4/15/19	Par has made a business decision to permanently discontinue the drug product
Quinapril (Pfizer)	5, 10, 20 mg tablets 10x10 unit dose blisters	11/12/2019	
Vinorelbine Tartrate Injection (Hospira, Inc.)	10 mg/mL; 50 mg/5mL Single Dose Onco-Tain Glass Fliptop Vial	4/16/2019	Discontinuation of the manufacture of the drug.
Vinorelbine Tartrate Injection (Hospira, Inc.)	10 mg/mL Single Dose Onco-Tain Glass Fliptop Vial	4/16/2019	Discontinuation of the manufacture of the drug.
Oxycodone Hcl (Teva)	5, 15, 30 mg tabs	11/7/2019	Teva made a business decision to discontinue manufacture of the drug product.
Divalproex Sodium Extended-Release Tablets (PAR)	250 mg (100, 500 ct), 500 mg (100, 500ct)	10/31/19	Par has made a business decision to permanently discontinue the drug product.
Darifenacin Hydrobromide Tablets (PAR)	ER 15 mg (30, 90ct), ER 7.5 mg (30, 90ct)	10/30/2019	Par has made a business decision to permanently discontinue the drug product.
Tolterodine Tartrate (Detrol LA) Extended Release Capsules	2 mg, blisters; 4 mg, blisters	10/1/2019	Discontinuation of the manufacturer of the drug
benzyl alcohol lotion	5% (50mg/g of lotion)	9/18/2019	Business decision to discontinue marketing in the US. This product discontinuation is not related to product quality, safety, or efficacy.
Stavudine/Mylan	20mg capsules, 40mg capsules	4/30/19 and 7/17/2019, respectively	n/a
Fenofibric Acid Delayed-Release Capsules/ Par and Mylan pharmaceuticals	45 mg, 90 count bottle, 135 mg, 90 count bottle	04/15/2019 05/02/2019	Par has made a business decision to permanently discontinue the drug product.
Doxycycline Hyclate Delayed Release; manufacturer: Mylan	15mg tablets	9/9/2019	Not listed
Flumazenil Injection/Mylan	0.1mg/1mL	7/19/2019	n/a
Carbidopa levodopa/Merck	50mg-200mg, 25mg-100mg	7/17/2019	To be discontinued on or near November 2019 and February 2020 respectively
Omeprazole Capsule/Teva	40mg capsule, 30,90,1000 count	7/17/2019	This product discontinuation is a business related decision.
Naratriplan Tablets /Mylan	1mg	7/17/2019	n/a
Magnevist Injection/	n/a	7/17/2019	n/a
Epirubicin HCl Injection/Cipla	2mg/1mL	7/17/2019	To be discontinued on or near September 2019
Rescriptor® (delavirdine)/ViiV healthcare	200mg	6/26/2019	The discontinuation was due to business reasons and is not due to any safety, efficacy or quality issues, and will be available until 1/2020
Hydromorphone HCl Extended-Release Tablets, CII/Teva	32 mg, 100 count; 16mg, 100 count; 12 mg, 100 count; 8 mg, 100 count	6/20/2019	This was a business-related decision to discontinue manufacturing these products.
Doxycycline Capsules/ Teva	50, 75, 100 mg capsules	4/29/2019	This product discontinuation is a business related decision.
Testosterone Gel 1%/ Par	2.5 g and 5 g, 30 packets	4/29/2019	Par has made a business decision to discontinue the drug product.
Ribavirin/ Merck Sharp & Dohme Corp	40 mg/mL	4/16/2019	To be discontinued on or near June 2019.
Lesinurad (ZURAMPIC) Tablets/ Ironwood Pharmaceuticals	200 mg tablets 5 and 30 count bottle	4/15/2019	Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Zurampic.
Lesinurad/Allopurinol (DUZALLO®) Tablets / Ironwood Pharmaceuticals	200/200mg tablets 5, 30, 90 count bottle, 200/300 mg tablets 5, 30, 90 count bottle	4/15/2019	Ironwood Pharmaceuticals, Inc. has made a business-related decision to discontinue Duzallo.
Nifedipine Extended-Release Tablet, USP / Par Pharmaceutical	30mg, 100, 500 count bottle, 60mg, 100 and 500count bottle, 90 mg, 100 count bottle	4/15/2019	Par has made a business decision to permanently discontinue the drug product.
Nystatin Cream, USP / Par Pharmaceutical	100,000 USP units per gram, 15 g, 30g, and 60g.	4/15/2019	Par has made a business decision to permanently discontinue the drug product.
lesinurad (DUZALLO and ZURAMPIC)	None listed	2/1/2019	Ironwood is discontinuing U.S. commercialization of lesinurad (DUZALLO and ZURAMPIC), effective February 1, 2019. This is a business decision and is not related to any efficacy, safety or clinical concerns with lesinurad. If you have been taking either DUZALLO or ZURAMPIC to treat your condition, please consult with your healthcare professional before making any decisions to stop treatment. Please work with your healthcare professional for an alternate treatment for your condition.
Emadine (emedastine difumarate)	0.05% ophthalmic solution 5mL in 1 Bottle (NDC 0065-0325-05)	1/29/2019	Novartis Pharmaceuticals has made a business decision to permanently discontinue this product.
ADAGEN (pegademase bovine)	Injection 250 units per mL	1/18/2019	The discontinuation of the manufacture of Adagen is due to the permanent shortage of the active ingredient. The discontinuation of the product is not due to product quality, safety, or efficacy concerns. Based on the demand in mid-January 2019, the inventory is estimated to runout by late-March 2019. Physicians can continue to treat ADA-SCID patients with another approved treatment for ADA-SCID. (NDC 57665-001-01)
Daklinza™ (daclatasvir)	30 mg and 60 mg tablets.	1/4/2019	Previously, the FDA announced the discontinuation of Daklinza 90 mg tablets with planned distribution ceasing in December 2018. — Bristol Myers Squibb has planned to cease distribution for Daklinza 30 mg and 60 mg tablets in June 2019. — All Daklinza tablets are now discontinued.